Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy

Open Access 20-04-2024 | Amphotericin B | ORIGINAL RESEARCH

A Retrospective Analysis of Central and Peripheral Metabolic Characteristics in Patients with Cryptococcal Meningitis

Authors: Jianglong Qin, Lanwei Nong, Qingdong Zhu, Zhizhong Huang, Fengyao Wu, Sijun Li

Published in: Neurology and Therapy

Login to get access

Abstract

Introduction

Most current treatment strategies and investigations on cryptococcal meningitis (CM) focus primarily on the central nervous system (CNS), often overlooking the complex interplay between the CNS and the peripheral system. This study aims to explore the characteristics of central and peripheral metabolism in patients with CM.

Methods

Patients diagnosed with CM as per the hospital records of the Fourth People’s Hospital of Nanning were retrospectively analyzed. Patients were divided into two groups, non-structural damage of the brain (NSDB) and structural damage of the brain (SDB), according to the presence of brain lesions as detected with imaging. Based on the presence of enlarged cerebral ventricles, the cases in the SDB group were classified into non-ventriculomegaly (NVM) and ventriculomegaly (VM). Various parameters of cerebrospinal fluid (CSF) and peripheral blood (PB) were analyzed.

Results

A significant correlation was detected between CSF and PB parameters. The levels of CSF-adenosine dehydrogenase (ADA), CSF-protein, CSF-glucose, and CSF-chloride ions were significantly correlated with the levels of PB-aminotransferase, PB-bilirubin, PB-creatinine (Cr), PB-urea nitrogen, PB-electrolyte, PB-protein, and PB-lipid. Compared with NSDB, the levels of CSF-glucose were significantly decreased in the SDB group, while the levels of CSF-lactate dehydrogenase (LDH) and CSF-protein were significantly increased in the SDB group. In the SDB group, the levels of PB-potassium, PB-hemoglobin(Hb), and PB-albumin were significantly decreased in the patients with VM, while the level of PB-urea nitrogen was significantly increased in these patients.

Conclusion

Metabolic and structural alterations in the brain may be associated with peripheral metabolic changes.
Literature
1.
Fisher KM, Montrief T, Ramzy M, Koyfman A, Long B. Cryptococcal meningitis: a review for emergency clinicians. Intern Emerg Med. 2021;16:1031–42.PubMedCrossRef
2.
Elsegeiny W, Marr KA, Williamson PR. Immunology of cryptococcal infections: developing a rational approach to patient therapy. Front Immunol. 2018;9:651.PubMedPubMedCentralCrossRef
3.
Rajasingham R, Smith RM, Park BJ, et al. global burden of disease of HIV-associated cryptococcal meningitis an updated analysis. Lancet Infect Dis Actions Search in PubMed Search in NLM Catalog Add to Search. 2017;17:873–81.
4.
Sarkis RA, Mays M, Isada C, Ahmed M. MRI findings in cryptococcal meningitis of the non-HIV population. Neurologist. 2015;19:40–5.PubMedCrossRef
5.
Makadzange AT, McHugh G. New approaches to the diagnosis and treatment of cryptococcal meningitis. Semin Neurol. 2014;34:47–60.PubMedCrossRef
6.
Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O. French Cryptococcosis Study Group Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4(2): e21.PubMedPubMedCentralCrossRef
7.
8.
Seilhean D, Duyckaerts C, Vazeux R, et al. HIV-1-associated cognitive/motor complex: absence of neuronal loss in the cerebral neocortex. Neurology. 1993;43:1492–9.PubMedCrossRef
9.
10.
Tater P, Pandey S. Post-stroke movement disorders: clinical spectrum, pathogenesis, and management. Neurol India. 2021;69:272–83.PubMedCrossRef
11.
Zhong Y, Zhou Z, Fang X, Peng F, Zhang W. Magnetic resonance imaging study of cryptococcal neuroradiological lesions in HIV-negative cryptococcal meningitis. Eur J Clin Microbiol Infect Dis. 2017;36:1367–72.PubMedCrossRef
12.
Anjum SH, Bennett JE, Dean O, Marr KA, Hammoud DA, Williamson PR. Neuroimaging of cryptococcal meningitis in patients without human immunodeficiency virus: data from a multi-center cohort study. J Fungi. 2023;9:594.CrossRef
13.
14.
Tater P, Pandey S. Post-stroke movement disorders: clinical spectrum, pathogenesis, and management. Neurol India. 2021;69:272–83.PubMedCrossRef
15.
16.
17.
Tahsili-Fahadan P, Geocadin RG. Heart-brain axis: effects of neurologic injury on cardiovascular function. Circ Res. 2017;120:559–72.PubMedCrossRef
18.
Taggart P, Critchley H, Lambiase PD. Heart-brain interactions in cardiac arrhythmia. Heart. 2011;97:698–708.PubMedCrossRef
19.
Seong J, Kang JY, Sun JS, Kim KW. Hypothalamic inflammation and obesity: a mechanistic review. Arch Pharm Res. 2019;42:383–92.PubMedCrossRef
20.
Wang Q, Liu Y, Han L, et al. Risk factors for acute stroke-associated pneumonia and prediction of neutrophil-to-lymphocyte ratios. Am J Emerg Med. 2021;41:55–9.PubMedCrossRef
21.
22.
Wang H, Deng QW, Peng AN, et al. beta-arrestin2 functions as a key regulator in the sympathetic-triggered immunodepression after stroke. J Neuroinflamm. 2018;15:102.CrossRef
23.
24.
Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev. 2019;99:949–1045.PubMedCrossRef
25.
Dechandt CRP, Ferrari GD, Dos Santos JR, et al. Energy metabolism and redox state in brains of wistar audiogenic rats, a genetic model of epilepsy. Front Neurol. 2019;10:1007.PubMedPubMedCentralCrossRef
26.
Besson M-T, Dupont P, Fridell Y-WC, Liévens J-C. Increased energy metabolism rescues glia-induced pathology in a Drosophila model of Huntington’s disease. Hum Mol Genet. 2010;19:3372–82.PubMedCrossRef
27.
Robinson PA, Bauer M, Leal MAE, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28:82–92.PubMedCrossRef
28.
Edate S, Albanese A. Management of electrolyte and fluid disorders after brain surgery for pituitary/suprasellar tumours. Horm Res Paediatr. 2015;83:293–301.PubMedCrossRef
29.
Nessel I, Michael-Titus AT. Lipid profiling of brain tissue and blood after traumatic brain injury. Semin Cell Dev Biol. 2021;112:145–56.PubMedCrossRef
30.
Li J, Imano H, Yamagishi K, et al. Serum albumin and risks of stroke and its subtypes - the Circulatory Risk in Communities Study (CIRCS) -. Circ J. 2021;85:385–92.PubMedCrossRef
31.
Pascoe MC, Skoog I, Blomstrand C, Linden T. Albumin and depression in elderly stroke survivors: an observational cohort study. Psychiatry Res. 2015;230:658–63.PubMedCrossRef
32.
33.
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26:223–7.PubMedCrossRef
34.
Tauber SC, Eiffert H, Kellner S, et al. Fungal encephalitis in human autopsy cases is associated with extensive neuronal damage but only minimal repair. Neuropathol Appl Neurobiol. 2014;40:610–27.PubMedCrossRef
35.
Chang YC, Stins MF, McCaffery MJ, et al. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun. 2004;72:4985–95.PubMedPubMedCentralCrossRef
36.
Shi M, Li SS, Zheng C, et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest. 2010;120:1683–93.PubMedPubMedCentralCrossRef
37.
Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009;77:120–7.PubMedCrossRef
38.
Woo YH, Martinez LR. Cryptococcus neoformans-astrocyte interactions: effect on fungal blood brain barrier disruption, brain invasion, and meningitis progression. Crit Rev Microbiol. 2021;47:206–23.PubMedPubMedCentralCrossRef
39.
Simpson IA. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol. 1994;32:546–51.CrossRef
40.
Alves VS, Leite-Aguiar R, Silva JPD, Coutinho-Silva R, Savio LEB. Purinergic signaling in infectious diseases of the central nervous system. Brain Behav Immun. 2020;89:480–90.PubMedPubMedCentralCrossRef
41.
Niccoli T, Cabecinha M, Tillmann A, et al. Increased glucose transport into neurons rescues abeta toxicity in Drosophila. Curr Biol. 2016;26:2291–300.PubMedPubMedCentralCrossRef
42.
Generoso JS, Thorsdottir S, Collodel A, et al. Dysfunctional glymphatic system with disrupted aquaporin 4 expression pattern on astrocytes causes bacterial product accumulation in the CSF during pneumococcal meningitis. mBio. 2022;13: e0188622.PubMedCrossRef
43.
Rottenberg DA, Moeller JR, Strother SC, Sidtis JJ, Navia BA, Dhawan V, Ginos JZ, Price RW. The metabolic pathology of the AIDS dementia complex. Ann Neurol. 1987;22(6):700–6.PubMedCrossRef
44.
Ferrucci A, Nonnemacher MR, Cohen EA, Wigdahl B. Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. Virus Res. 2012;167:358–69.PubMedCrossRef
45.
Velasquez S, Prevedel L, Valdebenito S, et al. Circulating levels of ATP is a biomarker of HIV cognitive impairment. EBioMedicine. 2020;51: 102503.PubMedCrossRef
46.
Tsai WC, Lien CY, Lee JJ, et al. The clinical characteristics of adult cryptococcal meningitis patients who died within one year of treatment with a focus on those with early mortality. J Clin Neurosci. 2019;67:80–4.PubMedCrossRef
47.
Shahan B, Choi EY, Nieves G. Cerebrospinal fluid analysis. Am Fam Physician. 2021;103:422–8.PubMed
48.
Parihar R, Shukla R, Baishya B, Kalita J, Haldar R, Misra UK. NMR based CSF metabolomics in tuberculous meningitis: correlation with clinical and MRI findings. Metab Brain Dis. 2022;37:773–85.PubMedCrossRef
49.
Shahan B, Choi EY, Nieves G. Cerebrospinal fluid analysis. Am Fam Physic. 2021;103:422–8.
50.
Yang Y-C, Liu S-H, Hsu Y-H, Wu Y-L, Chu P-T, Lin P-C. Cerebrospinal fluid predictors of shunt-dependent hydrocephalus after hemorrhagic stroke: a systematic review and meta-analysis. Neurosurg Rev. 2022;45:1847–59.PubMedCrossRef
51.
Schousboe A. Content of ATP in cultivated neurons and astrocytes exposed to balanced and potassium-rich media. Neurochem. 1970;17:1501–4.CrossRef
52.
Brekke E. Glucose and intermediary metabolism and astrocyte-neuron interactions following neonatal hypoxia-ischemia in rat. Neurochem Res. 2017;42:115–32.PubMedCrossRef
53.
Zhang C, Tan Z, Tian F. Impaired consciousness and decreased glucose concentration of CSF as prognostic factors in immunocompetent patients with cryptococcal meningitis. BMC Infect Dis. 2020;20:69.PubMedPubMedCentralCrossRef
54.
Croteau E. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Exp Gerontol. 2018;107:18–26.PubMedCrossRef
55.
Chen SHM, Stins MF, Huang SH, et al. Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol. 2003;52:961–70.PubMedCrossRef
56.
Gerhart DZ, Broderius MA, Borson ND, Drewes LR. Neurons and microvessels express the brain glucose transporter protein GLUT3. Proc Natl Acad Sci USA. 1992;89:733–7.PubMedPubMedCentralCrossRef
57.
Banerjee D, Bloom ALM, Panepinto JC. Opposing PKA and Hog1 signals control the post-transcriptional response to glucose availability in Cryptococcus neoformans. Mol Microbiol. 2016;102:306–20.PubMedPubMedCentralCrossRef
58.
59.
Hegen H, Walde J, Auer M, Deisenhammer F. Cerebrospinal fluid:serum glucose ratio in the ventricular and lumbar compartments: implications for clinical practice. Eur J Neurol. 2017;25:373–9.PubMedCrossRef
60.
61.
62.
Jiao FY, Cao HC, Liu ZY, Wu S, Wong HB. The use of blood glucose/cerebrospinal fluid glucose ratio in the diagnosis of central nervous system infection in infants and children. J Singapore Paediat Soc. 1992;34:191–8.
63.
Zheng H, Chen Q, Xie Z, et al. A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset. Eur J Clin Microbiol Infect Dis. 2016;35:299–303.PubMedCrossRef
64.
Abassi M, Bangdiwala AS, Nuwagira E, et al. Cerebrospinal fluid lactate as a prognostic marker of disease severity and mortality in cryptococcal meningitis. Clin Infect Dis. 2021;73:e3077–82.PubMedCrossRef
65.
Huang Y, Zou J, Zhang K, Li H, Hu D, Liao W, Zhang L, Pan W, et al. Prediction of hospital discharge outcome from changes in cerebrospinal fluid/serum albumin quotient and cerebrospinal fluid lactate dehydrogenase in patients with cryptococcal meningitis. Future Microbiol. 2022;17:223–33.PubMedCrossRef
66.
67.
Mächler P. In vivo evidence for a lactate gradient from astrocytes to neurons. Cell Metab. 2016;23:94–102.PubMedCrossRef
68.
Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347:1362–7.PubMedCrossRef
69.
Gao C, Wang C, Liu B, et al. Intermittent hypoxia preconditioning-induced epileptic tolerance by upregulation of monocarboxylate transporter 4 expression in rat hippocampal astrocytes. Neurochem Res. 2014;39:2160–9.PubMedCrossRef
70.
71.
Gao C. Intermittent hypoxia preconditioning-induced epileptic tolerance by upregulation of monocarboxylate transporter 4 expression in rat hippocampal astrocytes. Neurochem Res. 2014;39:2160–9.PubMedCrossRef
72.
Brekke E. Glucose and intermediary metabolism and astrocyte-neuron interactions following neonatal hypoxia-ischemia in rat. Neurochem Res. 2017;42:115–32.PubMedCrossRef
73.
Nussinovitch M, Finkelstein Y, Elishkevitz KP, et al. Cerebrospinal fluid lactate dehydrogenase isoenzymes in children with bacterial and aseptic meningitis. Transl Res. 2009;154:214–8.PubMedCrossRef
74.
Kellogg RT, Park MS, Snyder MH, et al. Establishment of age- and sex-specific reference cerebral ventricle volumes. World Neurosurgery. 2023;175:e976–83.PubMedCrossRef
75.
Mangoni AA, Zinellu A. A systematic review and meta-analysis of serum concentrations of ischaemia-modified albumin in acute ischaemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage. Biomolecules. 2022;12:653.PubMedPubMedCentralCrossRef
76.
Sekhon MS, McLean N, Henderson WR, Chittock DR, Griesdale DEG. Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury. Crit Care Med. 2012;16:R128.
77.
78.
79.
Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002;8:1376–82.PubMedCrossRef
80.
Lopez-Gambero AJ, Martinez F, Salazar K, Cifuentes M, Nualart F. Brain glucose-sensing mechanism and energy homeostasis. Mol Neurobiol. 2019;56:769–96.PubMedCrossRef
81.
Sprague JE, Arbeláez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev. 2011;9:463–73.PubMedPubMedCentral
82.
Simon Á, Oláh J, Komlósi I, et al. Changes in expression of neuropeptides and their receptors in the hypothalamus and gastrointestinal tract of calorie restricted hens. Acta Biol Hung. 2017;68:237–47.PubMedCrossRef
83.
84.
Akmayev IG. Popov AP Morphological aspects of the hypothalamic-hypophyseal system. VII. The tanycytes_ Their relation to the hypophyseal adrenocorticotrophic function. An ultrastructural study. Cell Tissue Res. 1977;180:263–82.PubMed
85.
Ebling FJP, Lewis JE. Tanycytes and hypothalamic control of energy metabolism. Glia. 2018;66:1176–84.PubMedCrossRef
86.
Imbernon M, Saponaro C, Helms HCC, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab. 2022;34:1054-1063.e1057.PubMedPubMedCentralCrossRef
Metadata
Title
A Retrospective Analysis of Central and Peripheral Metabolic Characteristics in Patients with Cryptococcal Meningitis
Authors
Jianglong Qin
Lanwei Nong
Qingdong Zhu
Zhizhong Huang
Fengyao Wu
Sijun Li
Publication date
20-04-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00610-z